{Reference Type}: Journal Article
{Title}: Breakthrough infection among healthcare personnel following exposure to COVID-19: Experience after one year of the world's largest vaccination drive.
{Author}: Das A;Khan S;Vidyarthi AJ;Gupta R;Mondal S;Singh S;Wundavalli L;Bhatnagar S;Singh UB;Chaudhry R;
{Journal}: J Family Med Prim Care
{Volume}: 12
{Issue}: 10
{Year}: 2023 Oct
暂无{DOI}: 10.4103/jfmpc.jfmpc_529_23
{Abstract}: <B>UNASSIGNED: </B>The COVID-19 vaccination drive globally was supposedly a game-changing event. However, the emerging variants of the virus and waning immunity over time posed new challenges for breakthrough infections. Standing at the frontline of defense against COVID-19, healthcare personnel (HCP) were vulnerable to such infections.<BR><B>UNASSIGNED: </B>This study estimates i) the vaccine breakthrough infections (VBI) among HCP following exposure to COVID-19 cases, and ii) the mean interval between the second dose of vaccine and laboratory-confirmed SARS-CoV-2 infection.<BR><B>UNASSIGNED: </B>A cross-sectional study was conducted including 385 HCP with a history of exposure to COVID-19 cases during January and February 2022. Demographic details and clinical and vaccination history were collected from the test forms and the Web-based hospital management system. Laboratory testing of COVID-19 was carried out by real-time RT-PCR test.<BR><B>UNASSIGNED: </B>The majority of the HCP were males (262; 68.05%) and nurses (180; 46.75%) by occupation. Two doses of vaccines were received by 278 (87.7%) HCP. VBI was confirmed in 185 (66.55%) HCP. No significant difference in VBI between the COVAXIN and COVISHIELD recipients (P = 0.69) was observed. The interval between the second dose and confirmed SARS-CoV-2 infection was significantly higher (P < 0.00001) in COVAXIN recipients (median 228 days) than in COVISHIELD recipients (median 95 days).<BR><B>UNASSIGNED: </B>The incidence of VBI was very high among the HCP, but not statistically different among the COVAXIN and COVISHIELD-recipients. Waning immunity over time suggests boosting immunity with a third dose because of emerging variants.